Mark Stein, MD
Urology · New York, NYNPI 1194726281
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,800 of the $16,206 with a category attached, or 85.2%. Janssen Global Services, LLC accounts for 85.2% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $7,734, more than ten times the $642 reported in 2019.
Across 84 payments — averaging $192.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Global Services, LLC$14K
- Pfizer$653
- Astellas Pharma US Inc$616
- Merck$236
- Valencia Technologies Corporation$210
- Dendreon Pharmaceuticals LLC$104
- plus $587 from 17 others
Across 8 payments — averaging $24,593 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$112K
- Astrazeneca UK Limited$52K
- Bayer$33K
What the payments were for
- Consulting fees$13,80085%
- Speaking & faculty fees$3302%
- Food & beverage$2,07613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Global Services, LLC | 2 | $13,800 |
| Pfizer | 10 | $653 |
| Astellas Pharma US Inc | 34 | $616 |
| Merck | 9 | $236 |
| Valencia Technologies Corporation | 1 | $210 |
| Dendreon Pharmaceuticals LLC | 3 | $104 |
| Myriad Genetic Laboratories, Inc. | 4 | $75 |
| Ironshore Pharmaceuticals Inc. | 1 | $74 |
| Coloplast | 3 | $65 |
| Tolmar, Inc. | 2 | $56 |
| Johnson & Johnson | 2 | $45 |
| Acerus Pharmaceuticals Corporation | 2 | $43 |
| Immunitybio, Inc. | 1 | $33 |
| Urogen Pharma, Inc. | 1 | $31 |
| Bioprotect Medical, Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Teleflex LLC | 1 | $22 |
| Civco Medical Instruments | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Optos, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$468
- eCoin Device Kit$210
- ORGOVYX$138
- TALZENNA$138
How this compares
$16,206 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $174,853 |
| MyrbetriqMirabegron | 163 | $158,655 |
| GemtesaVibegron | 135 | $122,463 |
| Mirabegron ErMirabegron | 18 | $13,003 |
| Tamsulosin Hcl | 563 | $8,867 |
| Tolterodine Tartrate ErTolterodine Tartrate | 52 | $6,385 |
| Solifenacin Succinate | 72 | $3,871 |
| Oxybutynin Chloride ErOxybutynin Chloride | 141 | $3,696 |
| Trospium Chloride ErTrospium Chloride | 25 | $3,661 |
| Tadalafil | 18 | $3,134 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $2,105 |
| Silodosin | 13 | $1,771 |
| Finasteride | 118 | $1,597 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 74 | $1,491 |
| Sildenafil Citrate | 44 | $1,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $616 | $333,508175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.